Arbutus Biopharma Corporation (ABUS)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 01:31PM EDT. Market open.
| Previous close | 2.6800 |
| Open | 2.7100 |
| Bid | 2.7200 x 200 |
| Ask | 2.7300 x 200 |
| Day's range | 2.7000 - 2.8500 |
| 52-week range | 1.6900 - 3.2900 |
| Volume | |
| Avg. volume | 1,389,806 |
| Market cap | 490.977M |
| Beta (5Y monthly) | 2.09 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Insider Monkey
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript May 2, 2024 Arbutus Biopharma Corporation misses on earnings expectations. Reported EPS is $-0.10178 EPS, expectations were $-0.1. Arbutus Biopharma Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, […]
- Simply Wall St.
Arbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Arbutus Biopharma ( NASDAQ:ABUS ) First Quarter 2024 Results Key Financial Results Revenue: US$1.53m (down 77% from 1Q...
- GuruFocus.com
Arbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Insights into Arbutus Biopharma Corp's Q1 performance, including financial updates and progress in clinical trials.
© 2024 Yahoo. All rights reserved.